Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.
The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.
Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.
The firm posted revenues of $530.5 million, with organic growth at 4 percent and acquisitions and currency effects adding 4 percent and 5 percent, respectively.
